FOAL PNEUMONIA

CAUSATIVE ORGANISM

*Rhodococcus equi* is a Gram-positive, pleomorphic, facultative, intracellular bacteria. The bacteria produces a capsular polysaccharide which can prevent its destruction by the host. It is parasitic in that it can survive and multiply within the alveolar macrophage of the host by interfering with phagosome-lysosome fusion.

THE DISEASE

*Rhodococcus equi* infection is a respiratory disease affecting young foals worldwide. *R. equi* primarily causes a serious and often fatal pneumonia. The disease can involve bronchial lymph glands, the gastrointestinal tract, and occasionally the joints. Infection usually occurs in the first 3 weeks of life, but may occur in foals up to 6 months of age. The incubation period appears to be 13–19 days. The specific way *R. equi* causes disease is still being investigated. Virulence of the organism and susceptibility of the foal are key factors. Virulence of the organism has been shown to be associated with the presence of a plasmid containing a gene for Virulence associated protein A (VapA). Increased susceptibility to infection and disease in foals less than 2 months old has been correlated with low or waning levels of passively derived *R. equi* antibodies. The organism can be isolated from fecal and soil samples. Transmission is probably by inhalation or possibly by ingestion.

Clinical signs may be acute, subacute or chronic. (It should be noted that foals will usually continue to suckle through the course of the disease.) Clinical signs include:

- Fever >38.8ºC for >12 hrs
  (Temperature spike in evening is typical);
- Elevated plasma fibrinogen levels (normal is <400mg/dl);
- Elevated platelets and neutrophils;
- Increase in resting respiratory rate >40/min;
- Increased diffuse bronchial sounds (may or may not cough);
- May have bilateral mucopurulent nasal discharge;
- Tachycardia;
- Pneumonia; and/or
- Lethargy/Depression.

Diagnosis is based on clinical observations, age group affected, trachiobronchial aspirations and culture, thoracic radiography, serologic evaluations, and predisposing factors (endemic *R. equi* disease). Infection usually occurs weeks before clinical signs are noticed. Ultrasonography of the lungs has been used successfully as an aid in early diagnosis. The following serologic tests can be used to aid in early diagnosis and treatment of the disease, sometimes even prior to exhibition of clinical signs.

The ELISA (enzyme-linked immunosorbence assay) titer can measure existing antibodies to *Rhodococcus equi* capsular specific IgG. The tests must be done in a test laboratory.

The SHI (synergistic hemolysis inhibition) test measures equifactor-neutralizing antibody. The test is sensitive but is difficult and time consuming.

The AGID (agar gel immunodiffusion) test detects antibody to soluble equifactors which are released by the organism from an active locus of infection. The presence of these antibodies reflect active infection.

*“Equifactors” are extracellular synergistic hemolysins of *R. equi*, which are also known as phospholipases.*

Antibiotic Therapy should be aggressive and should continue until radiographic changes and fibrinogen levels have returned to normal and remain so for 7–14 days. Therapy may be necessary for 4–8 weeks. Adjuncts to antibiotic therapy may include expectorants and bronchodilators. Rifampin and a macrolide antibiotic in combination are currently the drugs of choice. They are synergistic and appear to be the only drugs that are effective once *R. equi* is in the macrophage. By using drug combinations, bacterial resistance that could occur with an individual drug could be delayed. Typical dosing is oral Rifampin 10mg/kg BID and azithromycin 10mg/kg SID.

Prevention of *R. equi* pneumonia can begin on the farm. This is especially important on those farms where the disease is endemic.
Environmental Factors | Corrective Measures
---|---
Dust | • Plant grass, cover area with gravel, wet area with sprinklers
Manure | • Remove.

**Farm Management**

<table>
<thead>
<tr>
<th>Corrective Measures</th>
</tr>
</thead>
</table>
| Identify foals at risk | • Daily observation of foals at rest
| | • Test for *R. equi* antibodies. Remove foals with low titers to an environment that will decrease their exposure to *R. equi*
| | • Monitor temperatures regularly
| | • Ultrasonographic chest scans^6^.

**IMMUNOPROPHYLAXIS PROGRAM**

*Rhodococcus equi* specific hyperimmune plasma has been shown to be effective prophylactic therapy in at-risk foals^10^. It should be noted that the passive transfer in the mare’s colostrum of antibodies to *R. equi* does not appear to be effective in the prevention of *R. equi* disease in her foal^11^. **Plasma must be administered before any significant exposure of the foal to *R. equi* in order to be a successful prophylaxis.** This should be in the first few days of life. The history of *R. equi* disease on the farm is important, as is the change in environmental conditions (temperature, dust conditions, humidity). Hyperimmune plasma should be administered again in 4–6 weeks. ELISA levels could be used as a guideline. By using a select group, ELISA titers could be measured at 2 week intervals to determine a trend for decline of antibody. It has been suggested that the plasma dose be repeated if the level drops below 20 ELISA units^12^.

**ASSISTANCE FOR ENDEMIC FARMS**

Plasvacc USA Inc. offers several methods of assisting farms with a known *R. equi* problem.

**LAB SERVICES**—Experienced laboratory personnel are standing by to run AGID tests to aid in diagnosing individual *R. equi* cases with results faxed directly to your clinic.

**HYPERIMMUNE PLASMA**—USDA licensed EQUIPLAS®REA and EQUIPLAS®R (*Rhodococcus Equi* Antibody, equine origin) are available from Plasvacc USA Inc. as an aid in management of *R. equi* to offer some protection for foals on endemic farms.

**REFERENCES**


**To order**

Please contact your local veterinary distributor